SCHEMBL17536609

SCHEMBL17536609

CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.60
FOLH1 Q04609 3/20 0.57
CTSD P07339 4/20 0.54
BACE1 P56817 4/20 0.54
GNPAT O15228 1/20 0.45
LMNA P02545 1/20 0.45
CTSB P07858 1/20 0.44
FPR1 P21462 1/20 0.43
FPR2 P25090 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21049237 1.00 ALDH1A1 (0.60) ALDH1A1FOLH1CTSDBACE1GNPAT
SCHEMBL21049238 1.00 ALDH1A1 (0.60) ALDH1A1FOLH1CTSDBACE1GNPAT
SCHEMBL17536608 1.00 ALDH1A1 (0.60) ALDH1A1FOLH1CTSDBACE1GNPAT
SCHEMBL17951689 0.99 ALDH1A1 (0.58) ALDH1A1FOLH1CTSDBACE1GNPAT
SCHEMBL16557150 0.94 ALDH1A1 (0.65) ALDH1A1FOLH1CTSDBACE1LMNA
SCHEMBL16557153 0.92 ALDH1A1 (0.54) ALDH1A1FOLH1CTSDBACE1CTSB
SCHEMBL20255738 0.90 CTSD (0.50) ALDH1A1FOLH1CTSDBACE1CTSB
SCHEMBL21012039 0.90 CTSD (0.50) ALDH1A1FOLH1CTSDBACE1CTSB
SCHEMBL7109161 0.89 GNPAT (0.50) ALDH1A1FOLH1CTSDBACE1GNPAT
SCHEMBL7109159 0.89 GNPAT (0.50) ALDH1A1FOLH1CTSDBACE1GNPAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250146050-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2025-05-08 US disclosed
US-20250122555-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2025-04-17 US disclosed
US-12139744-B2 Stabilisation of biological samples QIAGEN GMBH (DE) 2024-11-12 US disclosed
US-12110533-B2 Stabilisation and isolation of extracellular nucleic acids QIAGEN GMBH (DE) 2024-10-08 US disclosed
EP-4397770-A1 STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS PreAnalytiX GmbH (CH) 2024-07-10 EP disclosed
EP-3401406-B1 STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS PREANALYTIX GMBH (CH) 2023-11-29 EP disclosed
US-11525155-B2 Stabilisation of biological samples QIAGEN GMBH (DE) 2022-12-13 US disclosed
US-20220364149-A1 STABILISATION OF BIOLOGICAL SAMPLES QIAGEN GMBH (DE) 2022-11-17 US disclosed
US-10314894-B2 Treatment of cardio-renal disease using PCSK6 THE CLEVELAND CLINIC FOUNDATION (US) 2019-06-11 US disclosed
US-20160058848-A1 TREATMENT OF CARDIO-RENAL DISEASE USING PCSK6 THE CLEVELAND CLINIC FOUNDATION 2016-03-03 US disclosed
CN-103221069-A Alumina nanoparticle bioconjugates and methods of stimulating an immune response using said bioconjugates PROVIDENCE HEALTH & SERVICES OREGON 2013-07-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122555-A1 STABILISATION OF BIOLOGICAL SAMPLES RNASE1, RNASEH1, EWSR1 ALDH1A1 3862/4885FOLH1 1594/4885CTSD 189/4885
US-12139744-B2 Stabilisation of biological samples RNASE1, RNASEH1, EWSR1 ALDH1A1 3862/4885FOLH1 1594/4885CTSD 189/4885
US-20250146050-A1 STABILISATION OF BIOLOGICAL SAMPLES RNASE1, RNASEH1, EWSR1 ALDH1A1 3862/4885FOLH1 1594/4885CTSD 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.